- document
-
Neves Sao Pedro, M. (author), Silva dos Santos, M. (author), Eppink, Michel H.M. (author), Ottens, M. (author)A major challenge in the transition to continuous biomanufacturing is the lack of process analytical technology (PAT) tools which are able to collect real-time information on the process and elicit a response to facilitate control. One of the critical quality attributes (CQAs) of interest during monoclonal antibodies production is aggregate...journal article 2022
- document
-
Neves Sao Pedro, M. (author), Klijn, M.E. (author), Eppink, Michel H.M. (author), Ottens, M. (author)The transition to continuous biomanufacturing is considered the next step to reduce costs and improve process robustness in the biopharmaceutical industry, while also improving productivity and product quality. The platform production process for monoclonal antibodies (mAbs) is eligible for continuous processing to lower manufacturing costs...review 2021
- document
-
Neves Sao Pedro, M. (author), Picanço Castanheira Da Silva, T. (author), Patil, Rohan (author), Ottens, M. (author)Continuous manufacturing is an indicator of a maturing industry, as can be seen by the example of the petrochemical industry. Patent expiry promotes a price competition between manufacturing companies, and more efficient and cheaper processes are needed to achieve lower production costs. Over the last decade, continuous biomanufacturing has...journal article 2021